Inventory

The components of inventory are summarized as follows:



(In millions)	As of March 31, 2016		As of December 31, 2015
Raw materials	$	249.5	$	213.0
Work in process	607.9		577.6
Finished goods	144.1		143.0
Total inventory	$	1,001.5	$	933.6

Balance Sheet Classification:
Inventory	$	964.6	$	893.4
Investments and other assets	36.9		40.2
Total inventory	$	1,001.5	$	933.6

Inventory included in investments and other assets in our condensed consolidated balance sheets primarily consisted of work in process.

As of March 31, 2016, our inventory included $23.5 million associated with our ZINBRYTA program and $33.8 million associated with the FLIXABI program, which have been capitalized in advance of regulatory approval. As of December 31, 2015, our inventory included $24.7 million associated with our ZINBRYTA program, $24.2 million associated with the FLIXABI program and $18.4 million associated with the BENEPALI program, which had been capitalized in advance of regulatory approval. In January 2016, the European Commission (EC) approved the marketing authorization application (MAA) for BENEPALI for marketing in the E.U.